Table 2. Open in new tab Decay kinetics...

	log₁₀ copies/mL
BP HIV-1-RNA
DTG + TAF/FTC (n = 15)	4.81 (4.30–5.43)	1.72 (1.57–2.20)	3.19 (2.92–3.40)	1.40 (1.20–1.69)	3.45 (3.10–3.72)	1.20 (1.20–1.43)	3.55 (3.10–4.04)	1.20 (1.20–1.65)
	[3.86–5.66]	[1.20–2.32]	[2.08–3.68]	[1.20–1.95]	[2.86–4.07]	[1.20–2.25]	[2.66–4.46]	[1.20–1.81]
DTG/3TC (n = 16)	4.74 (4.12–5.20)	1.70 (1.26–2.00)	3.10 (2.88–3.44)	1.20 (1.20–1.49)	3.45 (2.92–3.85)	1.20 (1.20–1.30)	3.54 (3.10–4.04)	1.20 (1.20–1.34)
	[3.90–5.61]	[1.20–3.49]	[0.41–3.74]	[1.20–1.82]	[2.10–4.24]	[1.20–1.88]	[2.34–4.37]	[1.20–1.95]
P value	0.318	0.545	0.830	0.338	0.770	0.922	0.446	0.770
Undetectable BP HIV-1-RNA
DTG + TAF/FTC, n (%)	0/15 (0.0)	11/15 (73.3)		11/15 (73.3)		14/15 (93.3)		13/15 (86.7)
DTG/3TC, n (%)	0/16 (0.0)	7/16 (43.8)		10/16 (62.5)		15/16 (93.8)		16/16 (100)
P value	1	0.192		0.794		0.4913		0.436
SP HIV-1-RNA
DTG + TAF/FTC (n = 15)	3.39 (2.78–3.54)	1.20 (1.20–1.68)	1.71 (1.41–2.24)	1.20 (1.20–1.65)	2.14 (1.41–2.34)	1.20 (1.20–1.20)	2.19 (1.41–2.34)	1.20 (1.20–1.20)
[2.41–5.59]	[1.20–3.51]	[0.84–2.518]	[1.20–2.51]	[1.13–3.07]	[1.20–1.81]	[0.97–4.39]	[1.00–2.20]
DTG/3TC (n = 16)	3.79 (3.09–5.21)	2.26 (1.20–3.33)	1.69 (0.66–2.34)	1.20 (1.20–2.47)	2.32 (1.39–3.18)	1.20 (1.20–1.20)	2.49 (1.68–4.01)	1.20 (1.20–1.20)
[1.20–6.18]	[1.20–4.01]	[0.00–3.53]	[1.20–3.10]	[0.00–4.17]	[1.20–2.15]	[0.00–4.98]	[1.20–1.20]
P value	0.086	0.101	0.470	0.446	0.318	1	0.140	0.545
Undetectable SP HIV-1-RNA
DTG + TAF/FTC, n (%)	0/15 (0.0)	11/15 (73.3)		11/15 (73.3)		14/15 (93.3)		13/15 (86.6)
DTG/3TC, n (%)	2/16 (12.5)	7/16 (53,8)		10/16 (62.5)		15/16 (93.8)		16/16 (100)
P value	0.484	0.149		0.704		1		0.226

log₁₀ copies/mL

Basal

Week 4

Dif. 0–4 week

Week 8

Dif. 0–8 week

Week 12

Dif. 0–12 week

Week 24

BP HIV-1-RNA

DTG + TAF/FTC (n = 15)

4.81 (4.30–5.43)

1.72 (1.57–2.20)

3.19 (2.92–3.40)

1.40 (1.20–1.69)

3.45 (3.10–3.72)

1.20 (1.20–1.43)

3.55 (3.10–4.04)

1.20 (1.20–1.65)

[3.86–5.66]

[1.20–2.32]

[2.08–3.68]

[1.20–1.95]

[2.86–4.07]

[1.20–2.25]

[2.66–4.46]

[1.20–1.81]

DTG/3TC (n = 16)

4.74 (4.12–5.20)

1.70 (1.26–2.00)

3.10 (2.88–3.44)

1.20 (1.20–1.49)

3.45 (2.92–3.85)

1.20 (1.20–1.30)

3.54 (3.10–4.04)

1.20 (1.20–1.34)

[3.90–5.61]

[1.20–3.49]

[0.41–3.74]

[1.20–1.82]

[2.10–4.24]

[1.20–1.88]

[2.34–4.37]

[1.20–1.95]

P value

0.318

0.545

0.830

0.338

0.770

0.922

0.446

0.770

Undetectable BP HIV-1-RNA

DTG + TAF/FTC, n (%)

0/15 (0.0)

11/15 (73.3)

14/15 (93.3)

13/15 (86.7)

DTG/3TC, n (%)

0/16 (0.0)

7/16 (43.8)

10/16 (62.5)

15/16 (93.8)

16/16 (100)

P value

0.192

0.794

0.4913

0.436

SP HIV-1-RNA

DTG + TAF/FTC (n = 15)

3.39 (2.78–3.54)

1.20 (1.20–1.68)

1.71 (1.41–2.24)

1.20 (1.20–1.65)

2.14 (1.41–2.34)

1.20 (1.20–1.20)

2.19 (1.41–2.34)

1.20 (1.20–1.20)

[2.41–5.59]

[1.20–3.51]

[0.84–2.518]

[1.20–2.51]

[1.13–3.07]

[1.20–1.81]

[0.97–4.39]

[1.00–2.20]

DTG/3TC (n = 16)

3.79 (3.09–5.21)

2.26 (1.20–3.33)

1.69 (0.66–2.34)

1.20 (1.20–2.47)

2.32 (1.39–3.18)

1.20 (1.20–1.20)

2.49 (1.68–4.01)

1.20 (1.20–1.20)

[1.20–6.18]

[1.20–4.01]

[0.00–3.53]

[1.20–3.10]

[0.00–4.17]

[1.20–2.15]

[0.00–4.98]

[1.20–1.20]

P value

0.086

0.101

0.470

0.446

0.318

0.140

0.545

Undetectable SP HIV-1-RNA

DTG + TAF/FTC, n (%)

0/15 (0.0)

11/15 (73.3)

14/15 (93.3)

13/15 (86.6)

DTG/3TC, n (%)

2/16 (12.5)

7/16 (53,8)

10/16 (62.5)

15/16 (93.8)

16/16 (100)

P value

0.484

0.149

0.704

0.226

	log₁₀ copies/mL
BP HIV-1-RNA
DTG + TAF/FTC (n = 15)	4.81 (4.30–5.43)	1.72 (1.57–2.20)	3.19 (2.92–3.40)	1.40 (1.20–1.69)	3.45 (3.10–3.72)	1.20 (1.20–1.43)	3.55 (3.10–4.04)	1.20 (1.20–1.65)
	[3.86–5.66]	[1.20–2.32]	[2.08–3.68]	[1.20–1.95]	[2.86–4.07]	[1.20–2.25]	[2.66–4.46]	[1.20–1.81]
DTG/3TC (n = 16)	4.74 (4.12–5.20)	1.70 (1.26–2.00)	3.10 (2.88–3.44)	1.20 (1.20–1.49)	3.45 (2.92–3.85)	1.20 (1.20–1.30)	3.54 (3.10–4.04)	1.20 (1.20–1.34)
	[3.90–5.61]	[1.20–3.49]	[0.41–3.74]	[1.20–1.82]	[2.10–4.24]	[1.20–1.88]	[2.34–4.37]	[1.20–1.95]
P value	0.318	0.545	0.830	0.338	0.770	0.922	0.446	0.770
Undetectable BP HIV-1-RNA
DTG + TAF/FTC, n (%)	0/15 (0.0)	11/15 (73.3)		11/15 (73.3)		14/15 (93.3)		13/15 (86.7)
DTG/3TC, n (%)	0/16 (0.0)	7/16 (43.8)		10/16 (62.5)		15/16 (93.8)		16/16 (100)
P value	1	0.192		0.794		0.4913		0.436
SP HIV-1-RNA
DTG + TAF/FTC (n = 15)	3.39 (2.78–3.54)	1.20 (1.20–1.68)	1.71 (1.41–2.24)	1.20 (1.20–1.65)	2.14 (1.41–2.34)	1.20 (1.20–1.20)	2.19 (1.41–2.34)	1.20 (1.20–1.20)
[2.41–5.59]	[1.20–3.51]	[0.84–2.518]	[1.20–2.51]	[1.13–3.07]	[1.20–1.81]	[0.97–4.39]	[1.00–2.20]
DTG/3TC (n = 16)	3.79 (3.09–5.21)	2.26 (1.20–3.33)	1.69 (0.66–2.34)	1.20 (1.20–2.47)	2.32 (1.39–3.18)	1.20 (1.20–1.20)	2.49 (1.68–4.01)	1.20 (1.20–1.20)
[1.20–6.18]	[1.20–4.01]	[0.00–3.53]	[1.20–3.10]	[0.00–4.17]	[1.20–2.15]	[0.00–4.98]	[1.20–1.20]
P value	0.086	0.101	0.470	0.446	0.318	1	0.140	0.545
Undetectable SP HIV-1-RNA
DTG + TAF/FTC, n (%)	0/15 (0.0)	11/15 (73.3)		11/15 (73.3)		14/15 (93.3)		13/15 (86.6)
DTG/3TC, n (%)	2/16 (12.5)	7/16 (53,8)		10/16 (62.5)		15/16 (93.8)		16/16 (100)
P value	0.484	0.149		0.704		1		0.226

Table 2.

Open in new tab

Decay kinetics of HIV-RNA in SP and cumulative incidence of participants with undetectable SP HIV-1-RNA according to the study design

	log₁₀ copies/mL
	Basal	Week 4	Dif. 0–4 week	Week 8	Dif. 0–8 week	Week 12	Dif. 0–12 week	Week 24
BP HIV-1-RNA
DTG + TAF/FTC (n = 15)	4.81 (4.30–5.43)	1.72 (1.57–2.20)	3.19 (2.92–3.40)	1.40 (1.20–1.69)	3.45 (3.10–3.72)	1.20 (1.20–1.43)	3.55 (3.10–4.04)	1.20 (1.20–1.65)
	[3.86–5.66]	[1.20–2.32]	[2.08–3.68]	[1.20–1.95]	[2.86–4.07]	[1.20–2.25]	[2.66–4.46]	[1.20–1.81]
DTG/3TC (n = 16)	4.74 (4.12–5.20)	1.70 (1.26–2.00)	3.10 (2.88–3.44)	1.20 (1.20–1.49)	3.45 (2.92–3.85)	1.20 (1.20–1.30)	3.54 (3.10–4.04)	1.20 (1.20–1.34)
	[3.90–5.61]	[1.20–3.49]	[0.41–3.74]	[1.20–1.82]	[2.10–4.24]	[1.20–1.88]	[2.34–4.37]	[1.20–1.95]
P value	0.318	0.545	0.830	0.338	0.770	0.922	0.446	0.770
Undetectable BP HIV-1-RNA
DTG + TAF/FTC, n (%)	0/15 (0.0)	11/15 (73.3)		11/15 (73.3)		14/15 (93.3)		13/15 (86.7)
DTG/3TC, n (%)	0/16 (0.0)	7/16 (43.8)		10/16 (62.5)		15/16 (93.8)		16/16 (100)
P value	1	0.192		0.794		0.4913		0.436
SP HIV-1-RNA
DTG + TAF/FTC (n = 15)	3.39 (2.78–3.54)	1.20 (1.20–1.68)	1.71 (1.41–2.24)	1.20 (1.20–1.65)	2.14 (1.41–2.34)	1.20 (1.20–1.20)	2.19 (1.41–2.34)	1.20 (1.20–1.20)
DTG + TAF/FTC (n = 15)	[2.41–5.59]	[1.20–3.51]	[0.84–2.518]	[1.20–2.51]	[1.13–3.07]	[1.20–1.81]	[0.97–4.39]	[1.00–2.20]
DTG/3TC (n = 16)	3.79 (3.09–5.21)	2.26 (1.20–3.33)	1.69 (0.66–2.34)	1.20 (1.20–2.47)	2.32 (1.39–3.18)	1.20 (1.20–1.20)	2.49 (1.68–4.01)	1.20 (1.20–1.20)
DTG/3TC (n = 16)	[1.20–6.18]	[1.20–4.01]	[0.00–3.53]	[1.20–3.10]	[0.00–4.17]	[1.20–2.15]	[0.00–4.98]	[1.20–1.20]
P value	0.086	0.101	0.470	0.446	0.318	1	0.140	0.545
Undetectable SP HIV-1-RNA
DTG + TAF/FTC, n (%)	0/15 (0.0)	11/15 (73.3)		11/15 (73.3)		14/15 (93.3)		13/15 (86.6)
DTG/3TC, n (%)	2/16 (12.5)	7/16 (53,8)		10/16 (62.5)		15/16 (93.8)		16/16 (100)
P value	0.484	0.149		0.704		1		0.226

	log₁₀ copies/mL
	Basal	Week 4	Dif. 0–4 week	Week 8	Dif. 0–8 week	Week 12	Dif. 0–12 week	Week 24
BP HIV-1-RNA
DTG + TAF/FTC (n = 15)	4.81 (4.30–5.43)	1.72 (1.57–2.20)	3.19 (2.92–3.40)	1.40 (1.20–1.69)	3.45 (3.10–3.72)	1.20 (1.20–1.43)	3.55 (3.10–4.04)	1.20 (1.20–1.65)
	[3.86–5.66]	[1.20–2.32]	[2.08–3.68]	[1.20–1.95]	[2.86–4.07]	[1.20–2.25]	[2.66–4.46]	[1.20–1.81]
DTG/3TC (n = 16)	4.74 (4.12–5.20)	1.70 (1.26–2.00)	3.10 (2.88–3.44)	1.20 (1.20–1.49)	3.45 (2.92–3.85)	1.20 (1.20–1.30)	3.54 (3.10–4.04)	1.20 (1.20–1.34)
	[3.90–5.61]	[1.20–3.49]	[0.41–3.74]	[1.20–1.82]	[2.10–4.24]	[1.20–1.88]	[2.34–4.37]	[1.20–1.95]
P value	0.318	0.545	0.830	0.338	0.770	0.922	0.446	0.770
Undetectable BP HIV-1-RNA
DTG + TAF/FTC, n (%)	0/15 (0.0)	11/15 (73.3)		11/15 (73.3)		14/15 (93.3)		13/15 (86.7)
DTG/3TC, n (%)	0/16 (0.0)	7/16 (43.8)		10/16 (62.5)		15/16 (93.8)		16/16 (100)
P value	1	0.192		0.794		0.4913		0.436
SP HIV-1-RNA
DTG + TAF/FTC (n = 15)	3.39 (2.78–3.54)	1.20 (1.20–1.68)	1.71 (1.41–2.24)	1.20 (1.20–1.65)	2.14 (1.41–2.34)	1.20 (1.20–1.20)	2.19 (1.41–2.34)	1.20 (1.20–1.20)
DTG + TAF/FTC (n = 15)	[2.41–5.59]	[1.20–3.51]	[0.84–2.518]	[1.20–2.51]	[1.13–3.07]	[1.20–1.81]	[0.97–4.39]	[1.00–2.20]
DTG/3TC (n = 16)	3.79 (3.09–5.21)	2.26 (1.20–3.33)	1.69 (0.66–2.34)	1.20 (1.20–2.47)	2.32 (1.39–3.18)	1.20 (1.20–1.20)	2.49 (1.68–4.01)	1.20 (1.20–1.20)
DTG/3TC (n = 16)	[1.20–6.18]	[1.20–4.01]	[0.00–3.53]	[1.20–3.10]	[0.00–4.17]	[1.20–2.15]	[0.00–4.98]	[1.20–1.20]
P value	0.086	0.101	0.470	0.446	0.318	1	0.140	0.545
Undetectable SP HIV-1-RNA
DTG + TAF/FTC, n (%)	0/15 (0.0)	11/15 (73.3)		11/15 (73.3)		14/15 (93.3)		13/15 (86.6)
DTG/3TC, n (%)	2/16 (12.5)	7/16 (53,8)		10/16 (62.5)		15/16 (93.8)		16/16 (100)
P value	0.484	0.149		0.704		1		0.226

Dif., difference; DTG/3TC, dolutegravir/lamivudine. Data expressed as median (IQR) and [range] unless otherwise stated. Undetectable HIV-1-RNA in BP was set to 1 log₁₀ copies/mL. Undetectable HIV-1-RNA in SP was set to 1.20 log₁₀ copies/mL.

This Feature Is Available To Subscribers Only